MedTrace Logo

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

NCT00003357 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-12-13

No results posted yet for this study

Summary

RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.

Conditions

Interventions

BIOLOGICAL

GM2-KLH vaccine

BIOLOGICAL

QS21

Sponsors & Collaborators

Principal Investigators

  • Teresa Ann Gilewski, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
2001-11-30
Completion
2001-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003357 on ClinicalTrials.gov